With success in vaccines, scientists turn mRNA on autoimmune disease

What is it?

STAT + is the premium entry service of STAT for in-depth coverage and analysis of biotechnology, pharmaceutical, policy and life science coverage. Our award-winning team covers news about Wall Street, policy developments in Washington, early scientific breakthroughs and clinical trials and disruption of health care in Silicon Valley and beyond.

What is included?

• Daily reporting and analysis
• The most comprehensive operational coverage of a powerhouse of reporters
• Subscriber newsletters only
• Daily newsletters to inform you about the most important industry news of the day
• STAT + talks
• Weekly opportunities to engage with our reporters and leading industry experts
• Exclusive business opportunities
• Excellent access to networking events for networking across the country
• The best reporters in the industry
• The most trusted and well-connected newsroom in the healthcare industry
• And much more
• Exclusive interviews with industry leaders, profiles and premium tools, such as our CRISPR Trackr.